Screener
Disc Medicine IRON Significant Segment Expense Category — Commercial Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Disc Medicine in its filing.
Tagged under the XBRL concept iron:CommercialExpense.
The source filing: Disc Medicine’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:33 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205192
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| DISC-3405 program external expense | (9,187) | (1,668) |
| Other external research and development expense | (2,165) | (1,832) |
| Internal and other research and development expense | (11,312) | (6,748) |
| Commercial expense | $(8,434) | $(1,921) |
| General and administrative expense | $(9,031) | $(6,858) |
| Stock-based compensation expense | $(11,946) | $(6,363) |
| Other segment items* | $6,020 | $5,861 |
| Net loss | $(63,504) | $(34,085) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Disc Medicine's significant segment expense category — commercial expense?
- Disc Medicine (IRON) reported significant segment expense category — commercial expense of -$8.43M in Q1 2026.
- How has Disc Medicine's significant segment expense category — commercial expense changed year-over-year?
- Disc Medicine's significant segment expense category — commercial expense decreased by 339.0% year-over-year, from -$1.92M to -$8.43M.
- What is the long-term trend for Disc Medicine's significant segment expense category — commercial expense?
- Over 2 years (2023 to 2025), Disc Medicine's significant segment expense category — commercial expense has grown at a 284.4% compound annual growth rate (CAGR), from -$1.01M to -$14.88M.
- What does significant segment expense category — commercial expense mean?
- This metric represents the costs incurred by the company to support the market launch, promotion, and distribution of its therapeutic candidates. It reflects the investment in commercial infrastructure and activities necessary to transition from clinical development to product commercialization. Monitoring this expense helps investors assess the company's readiness and financial commitment to bringing its hematologic therapies to market.
Ask your AI about Disc Medicine's significant segment expense category — commercial expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude